Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032352 · ClinicalTrials.gov registry record
Predictive Assay for Decision Making in Adjuvant Therapy
A clinical trial, sponsored by Insight Molecular Diagnostics.
- Terminated
- Registry status
- 55
- Enrollment target
NCT05032352 is a clinical trial that was terminated before completion, run by Insight Molecular Diagnostics. The registered enrollment target is 55 participants.
The verdict
NCT05032352 was terminated before completion, sponsored by Insight Molecular Diagnostics.
- TERMINATED
- Registry status
- 55 participants
- Enrollment target
Study Summary
Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA (tumor \< or = 5cm, node negative) Non-squamous Non-Small Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay DetermaRx being Considered for Adjuvant Platinum-based chemotherapy or other adjuvant therapy versus Observation
Interventions
- OTHER Observation
- DRUG Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2022-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05032352
The ClinicalTrials.gov registry entry for NCT05032352 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insight Molecular Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Observation is the first listed.
NCT05032352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05032352 about?
NCT05032352 is a clinical study titled "Predictive Assay for Decision Making in Adjuvant Therapy". Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA (tumor \< or = 5cm, node negative) Non-squamous Non-Small Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay DetermaRx being Considered for ...
What is the current status of trial NCT05032352?
This trial is currently terminated. The enrollment target is 55 participants. The study started on 2022-01-28. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05032352?
The interventions under investigation include: Observation (OTHER), Adjuvant (DRUG).
Who is sponsoring clinical trial NCT05032352?
This trial is sponsored by Insight Molecular Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.